
Australia Approves First Vaccine for Infectious Respiratory Virus for Over 60s
Australia’s Therapeutic Goods Association (TGA) has approved the use of the protein-based immune-boosting vaccine Arexvy to combat the respiratory syncytial virus (RSV). The vaccine will be available on prescription for those over 60. RSV is one of 200 cold-causing viruses and is considered contagious and produces symptoms such as a runny nose, cough, fever, sore throat, and body aches. In rare instances, more serious chest infections like pneumonia or bronchiolitis, ear infections, and worsening asthma can develop. It typically affects children, but people over 60, and those with comorbidities and diminished immunity are more likely to become severely ill and require hospitalisation. In 2023, reported cases of RSV increased compared to 2022, with large numbers being seen in every state—barring Queensland....
